Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808934 | 0.92 | SMN1; SMN2 (0.33) | MEN1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL3803542 | 0.89 | CRHR1 (0.33) | LMNAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL9980819 | 0.81 | CRHR1 (0.40) | ATMMEN1LMNAKMT2AMAPT | |
| SCHEMBL3808926 | 0.73 | CRHR1 (0.39) | MAPTALDH1A1 | |
| SCHEMBL3803535 | 0.70 | CRHR1 (0.43) | MAPTALDH1A1 | |
| SCHEMBL12027414 | 0.66 | MEN1 (0.42) | MEN1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL9694131 | 0.63 | LMNA (0.47) | LMNAKMT2AMAPTALDH1A1POLB | |
| SCHEMBL8840628 | 0.60 | SMN1; SMN2 (0.50) | MEN1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL5843263 | 0.59 | MAPT (0.43) | MAPTALDH1A1POLBHPGDSMN1; SMN2 | |
| SCHEMBL19554980 | 0.59 | KDM4E (0.42) | MEN1LMNAKMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179919-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | EMORY UNIVERSITY (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130287687-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | UNIV EMORY (US) | 2013-10-31 | — | — | US | disclosed |
| US-8551996-B2 | Compounds, compositions, methods of synthesis, and methods of treatment | EMORY UNIVERSITY (US) | 2013-10-08 | — | — | US | disclosed |
| US-20110305636-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179919-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | CRH, CRHR1, CRHR2 | ATM 3515/4885MEN1 321/4885LMNA 3311/4885 |
| US-20110305636-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | CRH, CRHR1, CRHR2 | ATM 3078/4885MEN1 141/4885LMNA 4152/4885 |
| US-20130287687-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | CRH, CRHR1, CRHR2 | ATM 3515/4885MEN1 321/4885LMNA 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.